Q2 2026
Fund IFinal1 review flag
Opening
# Hemrock Ventures — Fund I
Q2 2026 Portfolio Update
Dear Limited Partners,
This letter covers Fund I for the quarter ended June 30, 2026. Three of the four companies grew in the quarter; GreenLeaf Bio's regulatory timeline slipped by more than a year, which we cover below.
---
### NovaTech
NovaTech had its strongest quarter: MRR reached $331K in June, up 12% on March, with net revenue retention of 122%. The company signed its two largest enterprise contracts. Its VP Sales left in May and the CEO is covering the role. Cash was $4.1M at June 30 against monthly burn of $98K.
---
### AdVantage
AdVantage grew MRR 8% in the quarter to $390K, and logo churn improved to 2.6% after small accounts moved to annual contracts. The programmatic TV beta is live with four retailers. The company does not plan to raise this year.
---
### RouteWise
RouteWise ended June at $6.6M ARR (March: $6.1M) with 81 customers and 69% gross margin. The London office opened in April and signed its first two UK customers. The company is planning a Series C for early 2027.
---
### GreenLeaf Bio
GreenLeaf Bio's EPA approval has moved from Q2 2026 to the second half of 2027, after the agency asked for another field season of data. Cash was $950K at June 30, about five months of runway. The company is raising a bridge with $600K of soft commitments and has asked the fund to participate.
All performance figures are gross unless stated as net. Company figures are as reported by the companies and are unaudited.
Hemrock Ventures
NovaTech
NovaTech had its strongest quarter: MRR reached $331K in June, up 12% on March, with net revenue retention of 122%. The company signed its two largest enterprise contracts. Its VP Sales left in May and the CEO is covering the role. Cash was $4.1M at June 30 against monthly burn of $98K.
AdVantage
AdVantage grew MRR 8% in the quarter to $390K, and logo churn improved to 2.6% after small accounts moved to annual contracts. The programmatic TV beta is live with four retailers. The company does not plan to raise this year.
RouteWise
RouteWise ended June at $6.6M ARR (March: $6.1M) with 81 customers and 69% gross margin. The London office opened in April and signed its first two UK customers. The company is planning a Series C for early 2027.
GreenLeaf Bio
GreenLeaf Bio's EPA approval has moved from Q2 2026 to the second half of 2027, after the agency asked for another field season of data. Cash was $950K at June 30, about five months of runway. The company is raising a bridge with $600K of soft commitments and has asked the fund to participate.